Home / Pipeline / AN2690 Topical Solution, 5% + Solution Vehicle Products AN2690 Topical Solution, 5% + Solution Vehicle
AN2690 Topical Solution, 5% + Solution Vehicle Phase 3 Completed ⚡ Active Interest: 40/100
Onychomycosis of Toenails
Onychomycosis of Toenails
Feb 1, 2011 → Feb 20, 2013
About AN2690 Topical Solution, 5% + Solution Vehicle AN2690 Topical Solution, 5% + Solution Vehicle is a phase 3 stage product being developed by Pfizer for Onychomycosis of Toenails. The current trial status is completed. This product is registered under clinical trial identifier NCT01302119. Target conditions include Onychomycosis of Toenails.
What happened to similar drugs? 2 of 9 similar drugs in Onychomycosis of Toenails were approved
Clinical Trials (2) NCT ID Phase Status Start Completion Indication NCT01302119 Phase 3 Completed Feb 1, 2011 Feb 20, 2013 Onychomycosis of Toenails NCT01270971 Phase 3 Completed Dec 1, 2010 Jan 8, 2013 Onychomycosis of Toenails
Product Company Stage Hype Score NVXT Solution + Vehicle of test product Sun Pharmaceutical Phase 2 NVXT topical + Placebo (Vehicle) Topical Sun Pharmaceutical Phase 2 SCH 56592 + SCH 56592 + SCH 56592 + SCH 56592 + Terbinafine + Placebo Merck Phase 2 terbinafine + Placebo + terbinafine + Placebo Novartis Phase 3 terbinafine hydrogen chloride + amorolfine nail lacquer Novartis Phase 3 terbinafine + Placebo + terbinafine + Placebo Novartis Phase 3 AN2690 Pfizer Phase 2 AN2690, 2.5% + AN2690, 5% + AN2690, 7.5% + Vehicle Pfizer Phase 2 AN2690 Solution, 5.0% + AN2690 Solution, 7.5% Pfizer Phase 2 AN2690 + AN2690 Pfizer Phase 2 Tavaborole 5% Topical Solution Pfizer Approved AN2690 Solution, 5.0% Pfizer Phase 2 AN2690, 2.5% + AN2690, 5% + AN2690, 7.5% + AN2690 Solution Vehicle Pfizer Phase 2 AN2690 Pfizer Phase 2 AN2690 Topical Solution, 5% + Solution Vehicle Pfizer Phase 3 AN2690 + AN2690 + AN2690 Pfizer Phase 1 Albaconozole + Placebo + Albaconozole + Placebo + Albaconozole + Placebo GSK plc Phase 1 Itraconazole 100mg capsules + Itraconazole 200mg tablets + Placebo tablets GSK plc Phase 3 Albaconazole tablet 400mg + Albaconazole 100mg capsules, then albaconazole 400mg tablet GSK plc Phase 1 Albaconazole 100mg + Albaconazole 200mg + Albaconazole 400mg + Albaconazole 400mg + Placebo 400 mg GSK plc Phase 2